FrancophonIA/ELRC3.0 huggingface dataset:
English: MINIMUM PARTICULARS TO APPEAR ON BLISTER WRAPPERS ALUMINIUM WRAPPER Advagraf 3 mg prolonged-release hard capsules (30, 50, 100 Aluminium Wrapper)
Estonian: MINIMAALSED NÕUDED, MIS PEAVAD OLEMA BLISTERPAKENDIL ALUMIINIUMPAKEND Advagraf 3 mg toimeainet prolongeeritult vabastavad kõvakapslid (30, 50, 100 tk alumiiniumpakendis)
English: myasthenia
Estonian: Simetikoon
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER Advagraf 5 mg prolonged-release hard capsules
Estonian: BLISTER Advagraf 5 mg toimeainet prolongeeritult vabastavad kõvakapslid
English: Insufficient function of the kidneys, reduced production of urine, impaired or painful urination General weakness, fever, collection of fluid in your body, pain and discomfort, increase of the enzyme alkaline phosphatase in your blood, weight gain, feeling of temperature disturbed - Insufficient function of your transplanted organ
Estonian: mao aeglustunud tühjenemine - Nahapõletik, põletustunne päikesevalgusega kokkupuutel - Liigesekahjustused - Valulik menstruatsioon ja ebanormaalne menstruaalne vereeritus - Mitme organi puudulikkus, gripilaadne haigus, suurenenud kuuma- ja külmatundlikkus,
English: Simeticone
Estonian: hüpertoonia
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER Advagraf 1 mg prolonged-release hard capsules
Estonian: BLISTER Advagraf 1 mg toimeainet prolongeeritult vabastavad kõvakapslid
English: Packs of 30, 50 and 100 prolonged-release hard capsules are available in blisters and packs of 30×1, 50×1 and 100×1 prolonged-release capsules are available in perforated unit-dose blisters.
Estonian: Pakendis on 30, 50 või 100 toimeainet prolongeeritult vabastavat kõvakapslit blistrites või 30×1, 50×1 ja 100×1 toimeainet prolongeeritult vabastavat kõvakapslit üheannuselistes perforeeritud blistrites.
English: Stevens Johnson syndrome Musculoskeletal and connective tissue disorders common:
Estonian: Lihaste, luustiku ja sidekoe kahjustused Sage:
English: EMA/300585/2012 EMEA/H/C/002622
Estonian: EMA/CHMP/158913/2012 EMEA/H/C/002622
English: It is available as tablets (50 mg).
Estonian: See on müügil tablettidena (50 mg).
English: The full EPAR for Riluzole Zentiva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Riluzole Zentiva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The main measure of effectiveness was the average survival time.
Estonian: Efektiivsuse põhinäitaja oli keskmine elulemus.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Riluzole Zentiva on 7 May 2012.
Estonian: Euroopa Komisjon andis Riluzole Zentiva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 7. mail 2012.
English: One of these studies was in older patients (over 75) and in patients with advanced disease.
Estonian: Üks nendest uuringutest hõlmas eakaid (üle 75-aastaseid) ja kaugelearenenud haigusega patsiente.
English: Riluzole stops the release of glutamate and this may help in preventing the nerve cells being damaged.
Estonian: Rilusool pidurdab glutamaadi vabanemist ja see aitab närvirakkude kahjustust ennetada.
English: In adult and elderly patients, it is given as 100 mg a day (50 mg every 12 hours).
Estonian: Täiskasvanutele ja eakatele antakse ravimit 100 mg ööpäevas (50 mg iga 12 tunni järel).
English: This medicine is the same as Rilutek, which is already authorised in the European Union (EU).
Estonian: See ravim on samane ravimiga Rilutek, millel juba on Euroopa Liidus müügiluba.
English: The Committee recommended that Riluzole Zentiva be given marketing authorisation.
Estonian: Komitee soovitas anda Riluzole Zentiva müügiloa.
English: EPAR summary for the public riluzole
Estonian: Kokkuvõte üldsusele rilusool
English: For more information about treatment with Riluzole Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Riluzole Zentivaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Riluzole Zentiva 50 mg/day was no more effective than placebo and 200 mg/day was no more effective than 100 mg/day.
Estonian: Riluzole Zentiva 50 mg ööpäevane annus ei olnud platseebost efektiivsem ja 200 mg ööpäevane annus ei olnud efektiivsem kui 100 mg ööpäevas.
English: The company that makes Rilutek has agreed that its scientific data can be used for Riluzole Zentiva (‘informed consent').
Estonian: Riluteki tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Riluzole Zentiva toetuseks (teabel põhinev nõusolek).
English: Other information about Riluzole Zentiva
Estonian: Muu teave Riluzole Zentiva kohta
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Riluzole Zentiva.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The most common side effects seen with Riluzole Zentiva (in more than 1 patient in 10) are nausea (feeling sick), asthenia (weakness) and abnormal liver tests (increased in liver enzymes levels).
Estonian: Riluzole Zentiva kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on iiveldus, asteenia (nõrkus) ja maksaanalüüside kõrvalekalded (maksaensüümide suur sisaldus veres).
English: This is a summary of the European public assessment report (EPAR) for Riluzole Zentiva.
Estonian: See on ravimi Riluzole Zentiva Euroopa avaliku hindamisaruande kokkuvõte.
English: The effectiveness of Riluzole Zentiva has been compared with that of placebo (a dummy treatment) in three studies involving a total of 1,282 patients.
Estonian: Riluzole Zentiva efektiivsust võrreldi platseeboga kolmes uuringus, milles osales 1282 patsienti.
English: Across the studies, Riluzole Zentiva was given as 50, 100 or 200 mg per day, and for up to 18 months.
Estonian: Uuringutes anti Riluzole Zentivat 50, 100 või 200 mg ööpäevas 18 kuu jooksul.
English: Looking at the results of the three studies together, over 18 months, patients who received Riluzole Zentiva 100 mg/day had an average survival time that was about two months longer than the survival time for patients who received placebo.
Estonian: Kolme uuringu tulemuste kokkuvõttena oli Riluzole Zentivat 100 mg päevas 18 kuu jooksul saanud patsientide keskmine elulemus ligikaudu 2 kuud pikem kui patsientidel, kes said platseebot.
English: For the full list of all side effects reported with Riluzole Zentiva, see the package leaflet.
Estonian: Riluzole Zentiva kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Riluzole Zentiva is a medicine containing the active substance riluzole.
Estonian: Riluzole Zentiva on ravim, mis sisaldab toimeainena rilusooli.
English: ALS is a form of motor neurone disease where attacks of the nerve cells responsible for sending instructions to the muscles lead to weakness, muscle waste and paralysis.
Estonian: Amüotroofiline lateraalskleroos on teatud motoorse närviraku haigus, kus lihaseid juhtivate närvirakkude impulsid põhjustavad nõrkust, lihaste kõhetumist ja halvatust.
English: They noted that there is no evidence that Riluzole Zentiva exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms, and that it has not been shown to be effective in the late stages of ALS.
Estonian: Inimravimite komitee märkis, et Riluzole Zentiva ravitoime kohta motoorfunktsioonile, kopsufunktsioonile, fastsikulatsioonidele, lihasjõule ja motoorsetele nähtudele, samuti efektiivsuse kohta amüotroofilise lateraalskleroosi hilisstaadiumides tõendid puuduvad.
English: Riluzole Zentiva is used to extend the patient's life, or the time before they need to use mechanical ventilation.
Estonian: Riluzole Zentivat kasutatakse patsiendi eluea pikendamiseks või mehaanilise ventilatsiooni vajaduse edasilükkamiseks.
English: Riluzole Zentiva must not be used in people who are hypersensitive (allergic) to riluzole or any of the other ingredients.
Estonian: Riluzole Zentivat ei tohi kasutada patsiendid, kes on rilusooli või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The average survival time was significantly longer for patients who received Riluzole Zentiva compared with patients who received placebo.
Estonian: Keskmine elulemus Riluzole Zentivat saanud patsientide rühmas oli oluliselt pikem võrreldes platseeborühma patsientide elulemusega.
English: The CHMP decided that Riluzole Zentiva's benefits are greater than its risks to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis.
Estonian: Inimravimite komitee otsustas, et Riluzole Zentiva kasulikkus eluea pikendamisel või amüotroofilise lateraalskleroosiga patsientide mehaanilise ventilatsiooni ajal on suurem kui sellega kaasnevad riskid.
English: Riluzole Zentiva should not be used in patients with any other form of motor neurone disease.
Estonian: Riluzole Zentivat ei tohi kasutada mis tahes muude motoorse närviraku haigustega patsientide raviks.
English: Riluzole Zentiva must not be used in patients who have liver disease or who have abnormally high levels of liver enzymes.
Estonian: Riluzole Zentivat ei tohi kasutada patsiendid, kellel on maksahaigus või ebanormaalselt suur maksaensüümide sisaldus veres.
English: Treatment with Riluzole Zentiva should only be started by a specialist doctor with experience in the management of motor neurone diseases.
Estonian: Ravi Riluzole Zentivaga tohib alustada ainult motoorse närviraku haiguste ravikogemusega eriarst.
English: The active substance in Riluzole Zentiva, riluzole, acts on the nervous system.
Estonian: Riluzole Zentiva toimeaine rilusool mõjub närvisüsteemile.
English: What is Riluzole Zentiva?
Estonian: Mis on Riluzole Zentiva?
English: Why has Riluzole Zentiva been approved?
Estonian: Miks Riluzole Zentiva heaks kiideti?
English: What is the risk associated with Riluzole Zentiva?
Estonian: Mis riskid Riluzole Zentivaga kaasnevad?
English: What benefit has Riluzole Zentiva shown during the studies?
Estonian: Milles seisneb uuringute põhjal Riluzole Zentiva kasulikkus?
English: The medicine was not more effective than placebo in the late stages of ALS.
Estonian: Amüotroofilise lateraalskleroosi hilisstaadiumites ei olnud ravim platseebost efektiivsem.
English: Riluzole Zentiva is used in patients with amyotrophic lateral sclerosis (ALS).
Estonian: Ravimit Riluzole Zentiva kasutatakse amüotroofilise lateraalskleroosiga patsientide raviks.
English: How has Riluzole Zentiva been studied?
Estonian: Kuidas Riluzole Zentivat uuriti?
English: How is Riluzole Zentiva used?
Estonian: Kuidas Riluzole Zentivat kasutatakse?
English: It is thought that the destruction of nerve cells in motor neurone disease may be caused by too much glutamate, a neurotransmitter (chemical messenger).
Estonian: Arvatakse, et glutamaadirohkus (keemiline virgatsaine) on motoorse närviraku haiguse puhul närviraku hävimise peamine põhjus.
English: What is Riluzole Zentiva used for?
Estonian: Milleks Riluzole Zentivat kasutatakse?
English: Riluzole Zentiva must also not be given to women who are pregnant or breast-feeding.
Estonian: Rasedad või imetavad patsiendid Riluzole Zentivat kasutada ei tohi.
English: The medicine can only be obtained with a prescription.
Estonian: Riluzole Zentiva on retseptiravim.
English: How does Riluzole Zentiva work?
Estonian: Kuidas Riluzole Zentiva toimib?
English: 19 May 2011
Estonian: 19. mai 2011
English: The European Commission issued a decision on 19 May 2011.
Estonian: Euroopa Komisjon tegi otsuse 19. mail 2011.
English: The medicine is available in all Member States of the European Union as well as Iceland and Norway.
Estonian: Ravimit turustatakse kõikides Euroopa Liidu liikmesriikides ning Islandil ja Norras.
English: What is Arimidex?
Estonian: Mis on Arimidex?
English: The recommended dose for adults, including elderly patients, is one 1 mg tablet once a day.
Estonian: Soovitatav annus täiskasvanutele, sh eakatele, on üks 1 mg tablett üks kord ööpäevas.
English: Arimidex is authorised in the EU via mutual recognition and national procedures.
Estonian: Arimidex kiideti Euroopa Liidus heaks vastastikuse tunnustamise menetluse ja riiklike menetluste kaudu.
English: • Pregnant or breast-feeding women.
Estonian: • rasedad või imetavad naised;
English: Arimidex must not be used in:
Estonian: Arimidexi ei tohi kasutada:
English: Why was Arimidex reviewed?
Estonian: Miks Arimidexi taotlus uuesti üle vaadati?
English: The Committee also harmonised other sections of the SmPC, including the Special Warnings, which state that tamoxifen and oestrogen-containing therapies should not be given with Arimidex and that Arimidex should be used with caution in patients with severe kidney problems or moderate to severe liver problems.
Estonian: Komitee ühtlustas ka ravimi omaduste kokkuvõtte muud lõigud, sealhulgas hoiatuste lõik, mille kohaselt ei tohi Arimidexi võtmise ajal saada tamoksifeeni ja östrogeeni sisaldavat ravi ning raskete neeruprobleemidega või mõõdukate või raskete maksaprobleemidega patsiendid peavad Arimidexi kasutama ettevaatusega.
English: Arimidex is a medicine that contains the active substance anastrozole.
Estonian: Arimidex on ravim, mis sisaldab toimeainena anastrosooli.
English: On 22 July 2010, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Arimidex in the EU.
Estonian: Euroopa Komisjon tegi 22. juulil 2010 inimravimite komiteele esildise, et ühtlustada Arimidexi müügiload Euroopa Liidus.
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Estonian: Esitatud andmete hindamise ja komitees toimunud teadusliku arutelu põhjal jõudis inimravimite komitee järeldusele, et ravimi omaduste kokkuvõtted, pakendi märgistused ja infolehed tuleb kogu ELis ühtlustada.
English: The European Medicines Agency has completed a review of Arimidex.
Estonian: Euroopa Ravimiamet on lõpetanud Arimidexi kohta tehtud taotluse läbivaatamise.
English: Arimidex belongs to a group of medicines called ‘aromatase inhibitors' which reduce the amount of the hormone oestrogen made in the body by blocking the action of an enzyme in the body called ‘aromatase'.
Estonian: Arimidex kuulub selliste aromataasi inhibiitoriteks nimetatavate ravimite rühma, mis vähendavad organismis toodetava östrogeeni (hormoon) hulka, blokeerides aromataasi (ensüüm) toime.
English: The same dose is recommended in patients with mild liver problems or with mild to moderate kidney problems.
Estonian: See annus sobib ka kergete maksaprobleemidega või kergete või mõõdukate neeruprobleemidega patsientidele.
English: Decreasing the production of oestrogen is a way of suppressing the growth of the breast cancer because the growth of breast tissue is stimulated by oestrogen.
Estonian: Östrogeeni tootmise vähendamine pärsib rinnanäärmevähi kasvu, sest östrogeen stimuleerib rinnakoe kasvu.
English: Questions and answers on Arimidex (anastrozole, 1 mg tablets)
Estonian: Teave Arimidexi (anastrosool, 1 mg tabletid) kohta
English: • Patients known to be hypersensitive (allergic) to the active substance anastrozole, or to any of the other ingredients.
Estonian: • patsiendid, kes võivad olla anastrosooli või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: For postmenopausal women with hormone receptor-positive early invasive breast cancer, the recommended duration of adjuvant endocrine treatment is five years.
Estonian: Varajase hormoonretseptor-positiivse invasiivse rinnanäärmevähiga menopausijärgses eas naistel on adjuvant-endokriinravi soovitatav pikkus viis aastat.
English: Questions and answers on Arimidex (anastrozole, 1 mg tablets) EMA/405019/2011
Estonian: Teave Arimidexi (anastrosool, 1 mg tabletid) kohta EMA/211634/2011
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Arimidex in the European Union (EU).
Estonian: Ameti inimravimite komitee jõudis järeldusele, et Arimidexi määramise teave tuleb Euroopa Liidus ühtlustada.
English: The company that markets Arimidex is AstraZeneca.
Estonian: Arimidexi toodab AstraZeneca.
English: • Treatment of hormone receptor-positive advanced breast cancer in postmenopausal women.
Estonian: • kaugelearenenud hormoonretseptor-positiivse rinnanäärmevähi ravi menopausijärgses eas naistel.
English: ‘Hormone receptor-positive' means that the cancer depends on the presence of oestrogen in order to grow.
Estonian: Hormoonretseptor-positiivne tähendab, et rinnanäärmevähi kasvuks on vaja östrogeeni;
English: • Adjuvant (add-on) treatment of hormone receptor-positive early invasive breast cancer in postmenopausal women, including those who have received two to three years of adjuvant tamoxifen (another anti-cancer medicine).
Estonian: menopausijärgses eas naistel, sealhulgas neil, kes on 2 kuni 3 aastat saanud adjuvantravi tamoksifeeniga (samuti vähivastane ravim).
English: It is used to treat breast cancer in women who have already gone through the menopause.
Estonian: Seda kasutatakse rinnanäärmevähi raviks menopausijärgses eas naistel.
English: Arimidex was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Estonian: Inimravimite vastastikuse tunnustamise ja detsentraliseeritud menetluse koordineerimisrühm nimetas Arimidexi ühtlustamist vajavaks ravimiks.
English: The European Commission issued a decision on 13 July 2011.
Estonian: Euroopa Komisjon tegi otsuse 13. juulil 2011.
English: If an atypical fracture is suspected in one leg then the other leg should also be examined.
Estonian: Kui ühel jalal kahtlustatakse ebatüüpilist murdu, tuleb uurida ka teist jalga.
English: The working party concluded that there was a need to conduct a further review to determine if any regulatory action was necessary.
Estonian: Töörühm järeldas, et vaja täiendavat läbivaatamist, et otsustada, kas on vaja võtta reguleerivaid meetmeid.
English: The Committee has also looked at epidemiological studies (studies of the causes and distribution of diseases in the population).
Estonian: Komitee tutvus ka epidemioloogiliste uuringutega (haiguste põhjuste ja elanikkonnas levimise uuringud).
English: Outcome of nine procedures under Article 20 of Regulation (EC) No 726/2004 and of one procedure under Article 31 of Directive 2001/83/EC as amended1
Estonian: Üheksa määruse (EÜ) nr 726/2004 artikli 20 kohase ja ühe muudetud direktiivi 2001/83/EÜ artikli 311 kohase esildismenetluse tulemused
English: What are bisphosphonates?
Estonian: Mis on bisfosfonaadid?
English: They should report to their doctor any pain, weakness or discomfort in the thigh or groin area, as this may be an indication of a possible fracture.
Estonian: Nad peavad teatama arstile mis tahes valust ja nõrkus- või ebamugavustundest reie- või kubemepiirkonnas, sest see võib viidata võimalikule luumurrule.
English: EMA/288359/2011 Rev.1 EMEA/H/A-31/1279
Estonian: EMA/288359/2011Red.1 EMEA/H/A-31/1279
English: The full changes made to the information to doctors and patients are available on the Agency's website.
Estonian: Arstidele ja patsientidele suunatud teabesse tehtud muudatuste täielik ülevaade on Euroopa Ravimiameti veebilehel.
English: 2 Bisphosphonates can be authorised nationally or centrally.
Estonian: Bisfosfonaadid võidakse heaks kiita riiklike või tsentraliseeritud menetluste teel.
English: Procedure numbers: EMEA/H/C/000595/A-20/0026, EMEA/H/C/000336/A-20/0036, EMEA/H/C/000101/A-20/0051, EMEA/H/C/000502/A-20/0025, EMEA/H/C/000501/A-20/0024, EMEA/H/C/000759/A-20/0012, EMEA/H/C/000619/A-20/0015, EMEA/H/C/001180/A-20/0005, EMEA/H/C/001195/A-20/0001 and EMEA/H/A-31/001279
Estonian: EMEA/H/C/000502/A-20/0025, EMEA/H/C/000501/A-20/0024, EMEA/H/C/000759/A-20/0012, EMEA/H/C/000619/A-20/0015, EMEA/H/C/001180/A-20/0005, EMEA/H/C/001195/A-20/0001 ja EMEA/H/A-31/001279
English: Bisphosphonates are medicines that are used to treat and prevent bone disorders.
Estonian: Bisfosfonaadid on ravimid, mida kasutatakse luukahjustuste raviks ja ennetamiseks.
English: At the same time, the European Commission requested the CHMP to carry out the same assessment for the centrally authorised medicines.
Estonian: Samal ajal palus Euroopa Komisjon, et inimravimite komitee hindaks samamoodi tsentraliseeritud menetlusega heaks kiidetud ravimeid.
English: Why were bisphosphonates reviewed?
Estonian: Miks bisfosfonaatide andmed uuesti üle vaadati?
English: Consequently, on 20 September 2010, the UK Medicines Regulatory Agency asked the CHMP to issue an opinion on bisphosphonate-containing medicines and atypical stress fractures and on whether the marketing authorisation for these medicines should be maintained, varied, suspended or withdrawn across the EU.
Estonian: Seetõttu palus Ühendkuningriigi ravimiamet 20. septembril 2010, et inimravimite komitee esitaks arvamuse bisfosfonaate sisaldavate ravimite ja ebatüüpiliste luu pingemurdude kohta ning selle kohta, kas kogu Euroopa Liidus tuleb nende ravimite müügiload säilitada, muuta, peatada või tagasi võtta.
English: They have been authorised in the EU since the early 1990s for hypercalcaemia (high levels of calcium in the blood) and the prevention of bone problems in patients with cancer.
Estonian: Euroopa Liidus on need heaks kiidetud alates 1990. aastate algusest hüperkaltseemia (vere liigse kaltsiumisisalduse) raviks ja luuprobleemide ennetamiseks vähipatsientidel.
English: They are available in the EU as tablets and as solutions for infusion (drip into a vein) under various trade names and as generic medicines2.
Estonian: Euroopa Liidus turustatakse neid tablettide ja infusioonilahustena (veeni tilgutatavate lahustena) mitme kaubandusliku nimetuse all ja geneeriliste ravimitena2.
English: • Doctors who are prescribing these medicines for the prevention or treatment of osteoporosis should regularly review the need for continued treatment, especially after five or more years of use.
Estonian: • Arstid, kes määravad kõnealuseid ravimeid osteoporoosi ennetamiseks või raviks, peavad ravi jätkamise vajaduse regulaarselt üle vaatama, eelkõige juhul, kui ravi kestab 5 aastat või kauem.
English: As a result, a warning was added to the product information of alendronic acidcontaining medicines across Europe.
Estonian: Selle tulemusena lisati kogu Euroopas alendroonhapet sisaldavate ravimite ravimiteabesse hoiatus.
English: The Committee noted that the number of reports of atypical fractures of the femur in users of bisphosphonates had increased since the 2008 review.
Estonian: Inimravimite komitee märkis, et teadete arv ebatüüpiliste reieluumurdude kohta bisfosfonaatide kasutajate hulgas on pärast 2008. aasta läbivaatamist suurenenud.
English: The current European public assessment reports for the nine centrally authorised medicines containing bisphosphonates concerned by these referrals (Aclasta, Adrovance, Bondenza, Bondronat, Bonviva, Fosavance, Ibandronic acid Teva, Vantavo and Zometa) can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Praegu kehtivad Euroopa avalikud hindamisaruanded üheksa tsentraliseeritud menetluse teel müügiloa saanud bisfosfonaate sisaldava ravimi kohta, mida käsitlevad kõnealused esildismenetlused (Aclasta, Adrovance, Bondenza, Bondronat, Bonviva, Fosavance, Ibandronic acid Teva, Vantavo ja Zometa), on Euroopa Ravimiameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.